KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to -$0.28.

  • Esperion Therapeutics' EPS (Weighted Average and Diluted) fell 6.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 15.62%. This contributed to the annual value of -$0.28 for FY2024, which is 86.21% up from last year.
  • As of FY2024, Esperion Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.28, which was up 86.21% from -$2.03 recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.28 during FY2024, and registered a low of -$9.31 during FY2021.
  • Over the past 3 years, Esperion Therapeutics' median EPS (Weighted Average and Diluted) value was -$2.03 (recorded in 2023), while the average stood at -$1.94.
  • In the last 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) plummeted by 78.01% in 2021 and then soared by 86.21% in 2024.
  • Esperion Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$5.23 in 2020, then plummeted by 78.01% to -$9.31 in 2021, then soared by 62.19% to -$3.52 in 2022, then soared by 42.33% to -$2.03 in 2023, then surged by 86.21% to -$0.28 in 2024.